FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to biotechnology and represents methods of treating an autoimmune disease involving administering into an individual a pharmaceutical composition containing a pharmaceutically acceptable carrier and a humanised anti-CD4-antibody, able to activate the regulatory C-cells CD4+CD25+, wherein the above antibody contains V-domain of H-chain containing the sequences DCRMY, VISVKSENYGANYAESVRG and SYYRYDVGAWFAY, and V-domain of L-chain containing the sequences RASKSVSTSGYSYIY, LASILES and QHSRELPWT; the above composition is administered subcutaneously into the individual in a dose of the humanized anti-CD4-antibody 20 to 200 mg or 8 to 60 mg/m2 of the individual's body surface, or 0.2 to 2 mg/kg. The present invention also discloses the pharmaceutical compositions applicable in the above methods of treating the autoimmune disease.
EFFECT: invention enables administering the pharmaceutical composition containing the humanised anti-CD4-antibody in higher doses losing no therapeutic effect and causing no intensification of any side effects.
46 cl, 20 dwg, 21 tbl, 8 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF TREATING AUTOIMMUNE DISEASE (VERSIONS) | 2009 |
|
RU2539110C2 |
AGENT FOR DISEASE TREATMENT | 2009 |
|
RU2540018C2 |
COMPOSITION FOR TREATING DISEASE | 2009 |
|
RU2531548C2 |
DRUGS FOR TREATING DISEASES | 2010 |
|
RU2598719C2 |
METHOD OF TREATING PSORIASIS (VERSIONS) | 2009 |
|
RU2497545C2 |
HUMANISED ANTI-IL-10 ANTIBODIES FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) | 2010 |
|
RU2587622C2 |
HUMANISED AHTH-CD4 ANTIBODY WITH IMMUNOSUPPRESSIVE PROPERTIES | 2004 |
|
RU2375375C2 |
METHODS AND COMPOSITIONS FOR ASTHMA TREATMENT USING ANTIBODIES AGAINST IL-13 | 2012 |
|
RU2640025C2 |
COMBINATION OF ANTI-EDb FIBRONECTIN ANTIBODY-IL-2 FUSION PROTEIN, AND MOLECULE BINDING TO B-CELLS, B-CELL PROGENITORS AND/OR THEIR CANCEROUS COUNTERPART | 2008 |
|
RU2484845C2 |
METHODS AND COMPOSITIONS FOR TREATING LUPUS | 2010 |
|
RU2607022C2 |
Authors
Dates
2015-01-27—Published
2009-03-10—Filed